{"id":"NCT00687804","sponsor":"Novartis","briefTitle":"A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study","officialTitle":"A Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of Ranibizumab (Intravitreal Injections) as Adjunctive and Mono-therapy in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2010-01","completion":"2012-01","firstPosted":"2008-06-02","resultsPosted":"2011-04-19","lastUpdate":"2013-04-01"},"enrollment":345,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":[]},{"type":"PROCEDURE","name":"Laser","otherNames":[]},{"type":"PROCEDURE","name":"Sham laser","otherNames":[]},{"type":"DRUG","name":"Sham to ranibizumab","otherNames":[]}],"arms":[{"label":"Ranibizumab 0.5 mg","type":"EXPERIMENTAL"},{"label":"Ranibizumab 0.5 mg + laser","type":"EXPERIMENTAL"},{"label":"Laser","type":"ACTIVE_COMPARATOR"}],"summary":"CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to diabetic macular edema.\n\nCRFB002D2301E1: A 24 month open-label extension study for participants who completed the 12 month core study evaluated the long-term safety and efficacy of ranibizumab (0.5 mg) as symptomatic treatment for visual impairment due to diabetic macular edema.","primaryOutcome":{"measure":"Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12","timeFrame":"Baseline through the end of study (Month 12)","effectByArm":[{"arm":"Ranibizumab 0.5 mg","deltaMin":64.7,"sd":10.07},{"arm":"Ranibizumab 0.5 mg + Laser","deltaMin":63.4,"sd":9.99},{"arm":"Laser","deltaMin":62.6,"sd":11.01}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":13,"countries":["Australia","Belgium","Canada","France","Germany","Greece","Hungary","Italy","Netherlands","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["26584450","26327116","25148789","24491642","23974915","21459215"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":41,"n":115},"commonTop":["Nasopharyngitis","Diabetic retinal oedema (Fellow eye)","Eye pain (Study eye)","Cataract (Study eye)","Hypertension"]}}